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I. Abstract
Implicit in cellular mechanisms essential for learning and memory, NMDA receptors
are heterotetrameric members of the family of ionotropic glutamate receptors. Activation of
the glutamate-specific receptor subunits results in the opening of ion channels, triggering an
excitatory pathway, which can be moderated by certain endogenous and exogenous
compounds. Previous research with the endogenous neurosteroids pregnenolone sulfate (PS)
and 3α-hydroxy-5-β-20-one sulfate (PregS) have indicated that the binding of these
neurosteroids to NMDA receptors containing the four A-D isoforms of the GluN2 subunit
affects current flow through them1. Binding of PS to NMDA receptors containing GluN2A or
GluN2B subunits causes an increased amount of current flow through the channel, whereas
binding of PS to receptors containing GluN2C and 2D subunits decreases current flow
through these channels. Binding of PregS to any NMDA receptor also decreases current flow.
Binding studies from our lab have determined that the neurosteroids PS and PregS bind to the
amino terminal domain (ATD) of both GluN2B and GluN2D subunits. The ATD segment
used in these studies consisted of residues 121-292. Binding of both neurosteroids was
monitored between pH 6.0 and 8.0. Results demonstrated that the binding of PS to GluN2B
and D ATDs occurred only between pH 6 and 6.5. PregS showed similar pH dependence for
the GluN2B ATD, although binding was restored at pH 8. The pH dependence of
neurosteroid binding suggests the importance of a protonated histidine residue in each
binding interaction. The GluN2B ATD segment contains one histidine at residue 127,
whereas the corresponding GluN2D ATD contains 3 histidines at residues 143, 182, and 202.
Results from preliminary structural and neurosteroid binding studies of His to Ala and Gln
mutations in the GluN2D ATD are presented.
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II. Background & Introduction
Glutamate is the main excitatory neurotransmitter in the mammalian brain. It is
involved in many cognitive functions, including learning and memory formation.
Ionotropic glutamate receptors (iGluRs) are a family of ligand-gated ion channels,
located in the postsynaptic neural membrane, which open as a response to glycine and the
neurotransmitter glutamate and are therefore highly controlled1. Glutamate binds to
specific receptor subunits via an extracellular binding site, inducing a conformational
change that causes a channel to open in the membrane. When the iGluRs are improperly
regulated, excess amounts of cations (Na+, Ca 2+, K+) enter the postsynaptic neural cell,
causing cell death1. This misregulation of iGluRs due to over-activity of the receptors has
been linked to neurodegenerative diseases such as Huntington’s, Alzheimer’s, and
Parkinson’s.

A. iGluR Family and Structure
Included in the iGluR family are alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA), kainate, delta, and N-methyl-D-aspartate (NMDA) receptors1.
Each member of the iGluR family is a tetrameric protein, encoded by 18 genes that often
undergo RNA editing and alternative splicing2. AMPA and kainate receptors are often
homotetramers, the NMDA receptor is a heterotetramer. Each subunit from the iGluR
family is modular, as shown in Fig. 1, and contains seven domains. They have an amino
terminal domain (ATD), which is critical for the interaction between subunits, an extracellular S1S2 neurotransmitter (ligand) binding domain (LBD), three membrane-

1

2
spanning domains, a re-entrant loop, which forms the pore when the receptor is
assembled, and a C-terminal tail that is intracellular1.
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Fig 1: Schematic representation of GluR2 domain architecture, composed of extracellular amino terminal
domain, S1S2 ligand-binding domain (LBD), three transmembrane-spanning regions, a re-entrant loop, and
an intracellular carboxyl terminal tail.

The NMDA heterotetramer is composed of two GluN1 subunits, which are one of
eight alternatively spliced versions from a single gene, and two GluN2 subunits (Fig. 2),
which are one of four versions from separate genes2. The GluN2 subunits are named as
GluN2A-D. As shown in Fig. 2, GluN1 subunits bind glycine, while GluN2 subunits bind
the neurotransmitter glutamate. Glutamate binds to the GluN2 subunit as an agonist, and
glycine binds to the GluN1 subunit as a coagonist.
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Fig 2: The schematic representation of NMDA receptor. NMDA receptor consists of four subunits with the
ion channel pore in the center. Each subunit is composed of an intracellular C-terminus, four membrane
domains (M1–4) and extracellular region, where glycine or glutamate binds3.

The iGluR family is divided according to sequence homology and agonist
specificity, creating functional heterogeneity that is important for the complex
functioning of glutamatergic neuro-transmission4. While both receptors are found on the
extrasynaptic plasma membranes, AMPA receptors are intracellularly associated with the
endoplasmic reticulum, golgi apparatus, and multi-vesicular bodies4. In contrast, the
majority of NMDA receptors are expressed on the surface of neurons, concentrated
around synaptic junctions4.

1. The Amino Terminal Domain
While there is much still left to learn about the ATD, recent years have greatly
elucidated its structure and function. Studies done on NMDA receptor assembly indicate
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that GluN1 and GluN2 amino terminal domains likely heterodimerize and subsequently
associate5. This association of two heterodimers is believed to play a key role in
determining correct NMDA receptor subunit assembly. The ATD was successfully
proven to control the kinetics of NMDA receptor deactivation. It was also determined that
the ATD- ligand binding domain linker has an important role in generating this effect,
and that transplantation of the ATD affected the gating properties of the NMDA receptor
subtypes concerned.

2. The S1S2 Ligand Binding Domain
Although there is currently only one crystal structure for a full-length iGluR,
crystal structures have been found for the isolated LBDs in 10 subunits of both NMDA
and AMPA receptors. In AMPA receptors, it has been shown that the LBD is the site of
action of positive allosteric modulators, some of which cause desensitization while others
slow excitatory current decay, and recent crystal structures of these GluA2 modulator
complexes have been solved6. The ligand binding domain consists of two lobes that close
together upon agonist binding, forming a clamshell-like structure7. In addition to the
elucidation of these crystal structures, free energy landscape measurements of the GluA2
LBD in apo and glutamate bound states shows multiple conformations of similar energy
for the apo protein, which is consistent with the growing idea of a highly dynamic
molecule8. Simulations have been used for studying the spontaneous opening and closing
of GluA2, GluK, and NMDA GluN2A subunit LBDs as well, which demonstrate a salt
bridge network surrounding the clamshell that likely acts as a ligand binding sensor to
trigger domain closure9.
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3. Full Length iGluR
The crystal structure of a full-length rat GluA2 AMPA receptor tetramer has
recently been determined using X-ray data to 3.6 Å resolution. While this resolution is
not enough to elucidate specific side chains, it is the first full-length crystal structure of
an iGluR tetramer to be found10. The crystal structure showed several interesting aspects
of the GluA2 structure, particularly a cross-over of subunits that form dimer pairs in the
layers of the amino terminal (ATD) and ligand binding (LBD) domains10 (Fig. 3). It
appears that the ATD and LBD tetramer assemblies are loosely packed, as evidenced by a
large cavity observed on the central axis of symmetry at the ATD and LBD interface10.

Fig 3: Domain organization in the GluA2 ion channel crystal structure (PDB 3KG2). (a) The four subunits
in the tetramer assembly are colored blue, yellow, red and green; the molecular surface representation
reveals key features of the structure, including its organization in layers, the cavity at the ATD and LBD
interface, and the large size of the extracellular domains compared to the ion channel. (b) ATD dimer
formed by chains A and B reveals a large separation of the LBD domains in this subunit pair; linkers that
connect the layered domains are indicated by black arrows that draw attention to the different
conformations of the LBD linkers in the A and B subunits. (c) LBD dimer formed by chains A and D
reveals a large separation of the ATD domains in this subunit pair 11.
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Additional studies on wild type GluA2 receptors revealed that AMPA receptor
assembly proceeds starting with the formation of dimers, during which the ATD couples
closely with the trans-membrane segments, whereas the ligand binding domains (LBDs)
wind up pushed to the side. For AMPA receptors, subunit exchange in the ATD and LBD
layers appears to be critical to tetramer assembly12.

B. PS & PREGAS
Several endogenous compounds, such as Zn (II), the polyamines spermine and
spermidine, and the sulfated neurosteroids pregnenolone sulfate (PS) and 3-α -hydroxy-5β-pregnan-20-one sulfate (PregS) have been shown to be involved in the regulation of the
iGluRs13. PregS is a representative member of neurosteroids that, as shown in Fig. 2,
inhibit the activity of NMDA receptors, as well as GABAA, AMPA, and kainate
receptors13. These neurosteroids have been shown to reduce open channel probability and
time, as well as increase receptor desensitization14. PregS has been demonstrated to be an
allosteric inhibitor of NMDA receptors, rather than an ion channel blocker or competitive
inhibitor with glutamate15. Studies have indicated that a PregS inhibitory binding site is
likely located on the GluN2 subunit, although the exact location is uncertain16. It is the
elucidation of this neurosteroid binding site that is the focus of this work.
PS, which is structurally similar to PregS except for one double bond at the
steroid A/B ring juncture and different orientations of the sulfate group that both
neurosteroids possess- β orientation in PS, and α orientation in PregS (Fig. 4), inhibits
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the activity of non-NMDA iGluRs but differentially regulates NMDA receptors17.
Potentiation with PS has been shown to induce a 200% rise in NMDA receptor response,
and is believed to be exerted allosterically, via binding to a potentiating site on the
receptor3. Studies have demonstrated that PS has dual inhibitory and potentiating activity
at NMDA receptors with GluN2A or B subunits, with potentiation prevailing in 2A or B
subunits but inhibition prevailing in NMDA receptors with GluN2C or D subunits18. In
studying PS potentiation it was found that the potentiating effect of the neurosteroid was
significantly stronger when PS was bound to the receptor prior to the agonist, nearly
400% compared to 80% potentiation when PS was simultaneously bound with
glutamate19. This indicates that the PS binding site might interact allosterically with the
glutamate binding site, although again the exact binding site of both neurosteroids in
question, PS and PregS, has yet to be elucidated.
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Fig 4: Neurosteroid structures of PS and PregS

One of the primary structural similarities of PS and PregS, shared with all steroids
that are capable of modulating NMDA receptor function, is the presence of a charged
group on the C3 of the steroid core, in the case of PS and PregS a sulfate group (Fig 4)20.
It has also been shown that more planar steroids, of which PS is a characteristic member
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due to its double bond, typically function as potentiators of NMDA receptor response.
PregS, characteristic of more ‘bent’ steroids, is also typical in its function as an inhibitory
neurosteroid21.
Our lab has shown that both PS and PregS bind to the S1S2 domain of the
GluN2B subunit of the NMDA receptor, but that they do not bind to the GluN2D S1S2
domain22. Binding of PS and PregS has been found to occur at the ATD of both GluN2B
and GluN2D subunits, although the exact binding site is currently unknown.
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III. RESULTS AND DISCUSSION

We hypothesized that neurosteroid binding to the GluN2B and GluN2D subunits
occurred at the amino terminal domain. Previous electrophysiology experiments
demonstrated that neurosteroids bind to an extracellular region of NMDA receptors,
although the exact location of this binding was uncertain. Previous experiments from our
lab demonstrated neurosteroid binding to the S1S2 LBD of AMPA receptors. Further
fluorescence experiments with NMDA receptors demonstrated that binding of the
neurosteroids takes place at the GluN2B S1S2 domain, but not the GluN2D S1S2
domain. This suggests that neurosteroid binding likely occurs at the ATD of both
subunits.
The ATDs of GluN2B and GluN2D subunits are about 400 amino acids long. A
BLAST homology search was used to determine possible structural domains of these
ATDs. With homology to a portion of the atrial natriuretic peptide clearance (ANP-C)
receptor precursor, amino acids 121-292 were chosen for cloning and over-expression.
To elucidate neurosteroid binding to the GluN2B and 2D ATDs, intrinsic
fluorescence studies were conducted to observe changes in fluorescence emission upon
addition of the neurosteroids to each ATD. Intrinsic fluorescence studies measure the
changes in emission of intrinsic fluors present in proteins, the amino acids tyrosine,
phenylalanine, and tryptophan. However, tyrosine’s fluorescence emission is easily
quenched and phenylalanine is known to fluoresce weakly. Therefore, the amino acid
tryptphan was the amino acid whose emission was measured for fluorescence studies.
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There are four tryptophans in this short GluN2B ATD, and three tryptophans in the short
GluN2D ATD.
With confirmation of the hypothesis that neurosteroid binding does occur at the
GluN2B and 2D ATDs came information that neurosteroid binding is pH dependent, with
binding lost after pH 6.5. It was therefore hypothesized that a specific amino acid residue,
histidine, played a critical role in neurosteroid binding. Mutations to alter histidine
residues were conducted and fluorescence studies were done in order to determine if
neurosteroid binding was altered.

A. Cloning, Growth, & Purification of Wild Type Domains
GluN2B and GluN2D ATDs were solubly expressed similarly to the S1S2
domains from GluN2D subunits23. Soluble protein over-expression proved possible after
transformation into Origami 2(DE3) cells.
Circular dichroism (CD) spectroscopy was conducted on wild type (wt) GluN2B
and GluN2D ATDS, both apo and bound to the neurosteroids PS and PregS to confirm
the presence of secondary structure (Fig. 5A,B). The crystal structure of the GluN2B
ATD is known (GluN2D has not yet been crystallized), and has been demonstrated to be
a mixture of α-helices and β-sheets (Fig. 5C). Far-UV CD spectroscopy confirmed the
purified GluN2D ATD to be folded and of mixed α-helical/β-sheet character, consistent
with known structures of the GluN2B ATDs (60% sequence similarity)24 (pdb id 3JPW
(Fig. 5C)).
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Fig. 5: CD spectra of wt GluN2B
ATD (5A) and GluN2D ATD (5B)
Conc. = 1.7 µM, Apo (- - -), with the
addition of 30 fold molar excess of
PS (•••) or PREGAS ( ___ ).

C

(5C) pdb structure of GluN2B ATDGluN2D ATD crystal structure not
determined. Residues 121-292 in
blue, His127 in green, residues 4-120
and 293-404 in white.

B. Neurosteroids bind to GluN2B and GluN2D ATDs
Intrinsic fluorescence studies demonstrated that both neurosteroids, PS and PregS,
bind to the GluN2B and GluN2D ATDs (Fig. 6A,B). Binding studies allowed for the
determination of the dissociation constant, Kd. Calculated Kd values indicate that both PS
and PregS bind weakly to the GluN2B and 2D ATDs (Fig. 6A,B). PS demonstrated
similar affinity for GluN2B and 2D ATDs. PregS showed a weaker binding affinity than
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PS for both ATDs, 2-fold less for the GluN2B ATD, and nearly 6-fold less for the
GluN2D ATD.

(A) 6.8 µM NMDA GluN2B ATD, pH 6.2

KD=502
±190 µM
PS

KD=1.1
±0.3 mM
PREGAS

(B) 2.1 µM NMDA GluN2D ATD, pH 6.0

KD=575
±278 µM

KD=3.4
±2.9 mM

PS

PREGAS

Fig. 6: Percent fluorescent quenching of PS and PregS to the GluN2B (A) and GluN2D (B) ATD.

C. Neurosteroid Binding to Wild Type ATD in pH Dependent Manner
In fluorescence binding studies with the endogenous neurosteroids PS and PregS,
it was found that both neurosteroids bound to the GluN2B and GluN2D ATDs, but only
at certain pH values (Table 1).
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pH 6.0

pH 6.5

GluN2B/2D ATD with PS

Y

Y

GluN2B ATD with PREGAS

Y

Y

GluN2D ATD with PregS

Y

Y

pH 7.0

pH 7.5

pH 8.0

Y

Y

Y

Table 1: pH values at which (30-fold molar excess) neurosteroid binding occurs to 6.8 µM
GluN2B and 2.1 µM 2D ATDs, from intrinsic fluorescence studies. “Y” indicates that binding
occurs, demonstrated by a change in fluorescence intensity.

Binding of PS and PregS to the ATD was found to occur at the lower pH values of
6.0 and 6.5, and was then lost at higher pH values. Binding was restored for PregS at the
higher pH of 8.0, while PS was still unable to bind to the ATDs at that pH value. The loss
of binding after pH 6.5 coincides with the ionization of the amino acid histidine, around
6.10. Histidine remains protonated at pH values lower than its pKa, but at pH values of 7
or higher, increasingly large proportions of histidine become neutral. It was hypothesized
that histidine, with its ability to both hydrogen bond and/or ionic bond, played a crucial
role in neurosteroid binding to the ATD. It was therefore decided to create two mutations
for each histidine residue present in the amino terminal domain, the first to glutamine,
which is capable of hydrogen but not ionic bonding, and the second to alanine, capable of
neither hydrogen nor ionic bonding. By studying whether these two mutants are capable
of binding to neurosteroids, more can be determined about the exact location of binding,
as well as the type of binding that neurosteroids rely on to bind to the ATD. Using the
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crystal structure of the GluN2B ATD (Fig. 5C), the histidine residues for both GluN2B
and GluN2D ATDs were mapped.
The work completed thus far focuses on the GluN2D ATD mutants H143A,
H182A, H202A, and H202Q. The remaining GluN2D ATD mutants, H143Q and H182Q,
are currently being purified. In addition, the GluN2B wild-type ATD, as well as the
H127A and H127Q 2B mutants, are in the process of purification.

D. Mutagenesis, Growth & Purification of GluN2D ATD mutants
The ATD of GluN2B has only 1 histidine (amino acid (aa) 127), which will help
locate the binding pocket. The ATD of GluN2D, however, has 3 histidines, aa 143, 182,
and 202, which makes identification of the binding pocket more challenging than for the
NR2B. Mutagenesis of these four histidines was conducted, changing each histidine to
alanine and glutamine. GluN2B and 2D mutant ATDs were solubly expressed according
to the protocols established for wild-type amino terminal domains. CD studies were also
conducted on two GluN2D mutants, histidine 143 to alanine (H143A) and histidine 202
to glutamine (H202Q) to confirm that the mutation did not result in the loss of secondary
structure (Fig. 7).

Fig. 7: CD spectra of H143A (blue) and H202Q (red) GluN2D ATD mutants (apo), 5.2 µM.
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Preliminary results showed that the H143A mutant maintained secondary
structure similar to that of the wild type GluN2D ATD, although the CD spectrum was
much weaker for the H202Q mutant than the H143A mutant (Fig. 7). Although only one
glutamine mutant was investigated, it seems that changing the histidine at 202 to
glutamine causes a significant degree of unfolding. This indicates that it is possible aa
202 is crucial for proper folding. Work is currently underway to measure CD spectra for
all mutants and compare to the wild type protein under the same conditions.

E. Fluorescence Studies of GluN2D ATD WT and His Mutants
Upon determining that wild type and mutant ATDs had secondary structure,
intrinsic fluorescence spectroscopy was conducted to determine if there was neurosteroid
binding to each ATD at five pH values- 6.0, 6.5, 7.0, 7.5, and 8.0 (Table 2, 3). For the
wild type protein there was not enough to conduct fluorescence at all pH values, so there
is no fluorescence data for wt at pH 7.0. This will be performed in the future.
Fluorescence of the wild type GluN2D ATD when bound to PS (Table 2) and PregS
(Table 3) demonstrated higher quenching of both neurosteroids at the lower pH values of
6.0 and 6.5, indicating greater binding.
Intrinsic fluorescence spectroscopy was conducted on four mutant GluN2D
ATDs- H143A, H182A, H202A, and H202Q at all five pH values. Upon binding of PS to
the three alanine mutations, there appears to be no significant deviation from the wild
type binding at the corresponding pH values (Table 2). Thus, although the histidine was
mutated, and therefore the ability of the ATD at that particular residue to hydrogen bond
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and/or ionic bond was eliminated, neurosteroid binding can still occur. This indicates that
either the histidine residues are not important for neurosteroid binding, individually or at
all, or perhaps that there are other residues nearby with similar pKas (such as glutamate
or cysteine in unique environments) that are affecting the ability of the neurosteroids to
bind. The H202Q mutant shows significantly lower ability to bind to PS at all pH values
(Table 2), however these results are complicated by the CD data (Fig. 7), indicating
significant unfolding of the mutant.
pH

GluN2D WT H143A

H182A

H202A

H202Q

6.0

24.7 ± 3.9

21.5 ± 2.32

16.3 ± 2.72

28 ± 7.28

6.7 ± 2.28

6.5

20.2 ± 2.9

9.9 ± 5.13

13.6 ± 2.33

18.7 ± 2.22

3.7 ± 2.84

7.0

No studies

8.9 ± 6.39

15.7 ± 0.95

19.2 ± 5.18

8.4 ± 2.8

7.5

6.8 ± 3.12

NQ

15.6 ± 1.43

17.8 ± 0.87

NQ

8.0

13.1 ± 2.5

15.4 ± 5.4

13.6 ± 1.6

18.3 ± 4.61

7.6 ± 3.6

Table 2: Intrinsic fluorescence quenching of GluN2D ATDs (5.2 µM) in presence of 30 molar
excess PS. Percent quenching is measured as (Fapo - Fneurosteroid / Fapo) x 100 with error included.
NQ indicates no quenching.

PregS, upon binding to the wild type and mutant ATDs, displayed similar
tendencies to PS. All three alanine mutants showed a lack of pH dependence, while the
H202Q mutant bound even more poorly to PregS than to PS (Table 3). It is currently
hypothesized that this decreased binding occurs because of the weaker secondary
structure of the H202Q mutant.
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pH

GLuN2D WT H143A

H182A

H202A

6.0

29.1 ± 5.57

17.4 ± 3.55 17.1 ± 4.28 26.6 ± 5.11

NQ

6.5

19.3 ± 2.02

18.7 ± 4.13 10.7 ± 2.9

NQ

7.0

No studies

13.0 ± 6.46 14.6 ± 2.77 21.6 ± 3.75

4.9 ± 2.4

7.5

6.9 ± 3.17

NQ

10.4 ± 2.49 12.6 ± 2.26

NQ

8.0

12.7 ± 3.17

NQ

11.5 ± 2.62 15 ± 2.67

NQ

21.9 ± 2.12

H202Q

Table 3: Intrinsic fluorescence quenching of GluN2D ATDs (5.2 µM) in presence of 30 molar
excess PregS. Percent quenching is measured as (Fapo - Fneurosteroid / Fapo) x 100 with error included.
NQ indicates no quenching.

F. CONCLUSIONS

After confirming that both neurosteroids bind to the GluN2B and GluN2D ATDs
in a pH dependent manner, it was hypothesized that histidine’s ability to hydrogen bond
or ionic bond is crucial to the binding of these neurosteroids. Based on preliminary
results, it appears that the binding of these neurosteroids is more complicated than
previously thought. It is possible that a glutamate or cysteine, which have pKas similar to
histidine in unique environments, could also affect neurosteroid binding. Understanding
the possible role of these histidines will allow for further elucidation of the neurosteroid
binding pocket in the ATD. Knowledge of this binding pocket would allow for
differentiation between potentiation and deactivation of the channel upon binding of the
neurosteroid to the ATD, which in turn could lead to possible therapeutic targets.
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IV. EXPERIMENTAL METHODS

A. Cloning
The ATDs for the NMDA GluN2B, GluN2D, and AMPA GluA2 subunits (amino
acids 121-292) were amplified using PCR (rat GluA2 cDNA from Mark Mayer). After
restriction digestion (NcoI/XhoI for GluA2 and GluN2D and NcoI/BamHI for GluN2B),
these inserts were ligated into similarly cut plasmid pET-GQ, (from Eric Gouaux), and
transformed into Origami 2(DE3) cells (Novagen). Colonies were screened by PCR and
then sequenced.

B. Mutagenesis
Site-directed mutagenesis was conducted using a QuikChange XL kit
(Stratagene), with primers designed according to Table 4. PCR reactions were set up
according to Table 5 and run at 95 °C for 2 min, followed by 18 cycles of 95 °C for 1
min, 68 °C for 50 sec, and 68 °C for 15 min, and ending with one cycle of 68 °C for 7
min. 1 µl Dpn1 restriction enzyme was then added to each PCR reaction, spun for 1 min,
and incubated at 37 °C for 60 min. 4 µl Dpn1-treated DNA were then transformed into
XL-10 ultracompetent cells (Stratagene). XL-10 plasmid DNA was transformed into
DH5-α competent cells, and next transformed into Origami 2 cells. They were then
sequenced.
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GluN2B H127A

5’-CCCATCCTGGGCATCGCTGGGGGCTCATCTAT-3’

GluN2B H127Q

5’-CCCATCCTGGGCATCCAAGGGGGCTCA-3’

GluN2D H143A

5’-GCGGCGCCGCCGGCCACGGCTACGAT-3’

GluN2D H143Q

5’-GCCGCCTTGCACGGCTACGA-3’

GluN2D H182A

5’-CAAGAAGGCCCGAGCGCCTGGGCACGC-3’

GluN2D H182Q

5’-AAGGCCCGTTGGCCTGGGGCACGC-3’

GluN2D H202A

5’-CAGCGCTCCTCGAGCCTCCCAGCCCACC-3’

GluN2D H202Q

5’-GCTGGGAGCAACGAGGAGC-3’

Table 4: Primer sequences

Mutant:

H202Q, H127Q

Buffer

5 µl

H143A, H143Q,
H182A, H182Q,
H202A
5 µl

dsDNA template

10 ng

60 ng

10 ng

Primer

125 ng

125 ng

31.25 ng

dNTP

1 µl

1 µl

1 µl

Quiksolution

3 µl

5 µl

none

(Standard)

Table 5: PCR reaction conditions for specific mutants

H127A

2.5 µl
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C. Protein over-expression and purification
An overnight of GluN2B or GluN2D ATD in Origami 2(DE3) was used to seed
1.5 L LB-kan (37 °C), with growth continued until an OD600 of 0.8 was reached. The
temperature was then lowered to 20 °C for 30 min followed by induction with 1 mM
IPTG. Growth was continued for 16-18 h at 20 °C, after which time the cells were
centrifuged for 10 min at 4 °C and 4,000 rpm. The cell pellets were resuspended in 50
mL buffer A (50 mM Tris, pH 8) containing 5 mM MgSO4, 0.5 mM PMSF, 0.3 mM
deoxycholic acid, and 16 µM lysozyme, and lysed by sonication. Lysed cells were
centrifuged at 12,500 rpm for 30 min at 4 °C, and the supernatant loaded onto a nickel
affinity column (~20 mL, Novagen) and rotated overnight at 4 °C. The column was
rinsed with 30 mL of 50, 100, 250, and 500 mM, and 1M imidazole in buffer A. Further
purification for the GluN2B or GluN2D ATD included anion exchange chromatography
(AEC, GE Q sepharose) at both pH 7.0 and 8.0 (buffer A) followed by size exclusion
chromatography (SEC, Superdex 75 10/300) at pH 6.0. The purity of each was
determined by SDS-PAGE.

D. Fluorescence
Intrinsic fluorescence spectroscopy was performed on a Cary Eclipse fluorometer
at 25 °C. All emission scans were acquired from 295-380 nm upon excitation at 280 nm.
Final protein concentrations are as specified in figures (GluN2D ATDs in buffer A). The
neurosteroids (Steraloids) were solubilized in methanol to 15 mM. A 30:1 molar ratio of
neurosteroids was added to each iGluR domain. For all fluorescence experiments: (i)
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before data acquisition, samples were incubated for thirty seconds in the sample holder;
(ii) to account for any effects methanol had on fluorescence intensity, protein spectra with
methanol were collected, allowing for direct comparison; (iii) each data set consisted of
three independent spectra of identically prepared samples. For the GluN2B and 2D wild
type studies, Kd values were determined by experiments with varying neurosteroid
concentration from 25-175 molar excess. A double reciprocal plot [1/ΔF = 1/((F ∞

Fo).Kd[L]) + 1/(F -Fo)], was used to determine Kd25.
∞

E. Circular Dichroism Spectroscopy
CD was performed using a JASCO spectrophotometer. 5.2 µM apo protein was
added for the GluN2D mutant studies. 1.7 µM GluN2B ATD was used for the wild-type
CD, with the addition of 30-fold molar excess of PS and PregS. The GluN2D ATD for
the wild-type CD studies was 1.8 µM, again with 30-fold molar excess of PS and PregS.
Data was collected from 205-250 nm, 5 times using binomial smoothing (Fig. 5A,B) and
15 times using means-movement smoothing ( Fig. 7). The spectrophotometer operated at
room temperature.
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V. FUTURE WORK
The most pressing work to be completed is the growth, purification, and
successful completion of ligand binding studies as well as CD studies on the remaining
GluN2D mutants (H182Q and H143Q) as well as GluN2B mutants (H127A and H127Q)
and the GluN2B wild type ATD. In addition to this, CD thermal denaturation studies will
be conducted to determine the relative stability of each mutant’s structure as compared to
the wild type ATD. KD studies are also planned, in order to elucidate the binding affinity
of neurosteroids for the mutant and wild type ATDs. Upon the completion of these
studies, double and triple mutants will also be explored, to elucidate if more than one
histidine residue at a time is important for neurosteroid binding, or if glutamate or
cysteine play a role.
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